CEFYBO   02669
CENTRO DE ESTUDIOS FARMACOLOGICOS Y BOTANICOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Melatonin protects the retinal pigmentary epithelium and photoreceptor damage within experimental nonexudative age related macular denegeration.
Autor/es:
ROMEO, HORACIO E.; ROSENSTEIN, RUTH E.; DIEGUEZ, HERNÁN H.; GONZÁLEZ FLEITAS, MARÍA F.; ALAIMO A; DORFMAN, DAMIÁN
Lugar:
Carlos Paz, Provincia de Córdoba
Reunión:
Congreso; XXXIV Reunión Anual de la SAN; 2019
Institución organizadora:
Sociedad Argentina de Investigación en Neurociencias
Resumen:
-MELATONIN PROTECTS THE RETINAL PIGMENTARY EPITHELIUM AND PHOTORECEPTOR DAMAGE WITHIN EXPERIMENTAL NON-EXUDATIVE AGE-RELATED MACULAR DENEGERATIONNon-exudative age-related macular degeneration (NE-AMD), the main causeof blindness in the elderly, is characterized by retinal pigment epithelium(RPE) and photoreceptors (PR) atrophy exclusively circumscribed to the macula.There are no effective therapeutic strategies that can prevent or delay theNE-AMD. It has been suggested that RPE oxidative damage plays an important rolein NE-AMD pathogenesis. Melatonin is an effective antioxidant and has proveneffects within several retinal neurodegenerative disorders. We have developed aNE-AMD model induced by superior cervical ganglionectomy (SCGx) in adultC57BL/6J mice, which reproduces NE-AMD hallmarks exclusively circumscribed tothe central temporal RPE/outer retina, a region comparable to the human macula.In this context, the aim of this work was analyzing the effect of melatonin onthe alterations induced by SCGx. Melatonin prevented the visual function, thedecrease in RPE melanin content and RPE65-inmunorreactivity, and the RPE and PRultrastructural alterations at 10 weeks post-SCGx. Moreover, melatoninprevented the decrease in mitochondrial mass (MitoTrackerRed (+) area, andlevels of specific mitochondrial proteins) as well as the increase in RPE andPR oxidative stress markers at 6 weeks post-SCGx. These findings suggest thatmelatonin could be a possible novel therapy for treat the dAMD.